MLYS
Mineralys Therapeutics, Inc. NASDAQ Listed Feb 10, 2023$30.12
After hrs
$30.90
+2.59%
Mkt Cap $2.0B
52w Low $12.59
50.0% of range
52w High $47.65
50d MA $27.20
200d MA $31.14
P/E (TTM)
-12.8x
EV/EBITDA
-13.4x
P/B
3.1x
Debt/Equity
0.0x
ROE
-23.9%
P/FCF
-17.2x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$27.20
200d MA
$31.14
Avg Volume
1.2M
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was i…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.52 | -0.40 | +22.5% | 26.99 | -4.4% | -3.0% | -4.7% | -7.3% | -11.4% | -13.7% | — |
| Nov 10, 2025 | AMC | -0.66 | -0.52 | +21.2% | 44.50 | -6.0% | +5.9% | +6.4% | -0.5% | -8.2% | -0.5% | — |
| Aug 12, 2025 | AMC | -0.78 | -0.66 | +15.4% | 13.51 | -3.0% | +0.4% | +4.6% | +7.5% | +13.5% | +7.1% | — |
| May 12, 2025 | AMC | -1.02 | -0.79 | +22.5% | 15.01 | +0.4% | +1.2% | +0.7% | +2.3% | +2.3% | +2.1% | — |
| Feb 12, 2025 | AMC | -1.00 | -0.98 | +2.0% | 10.63 | -4.5% | -4.0% | -3.7% | -9.7% | -12.3% | -10.3% | — |
| Nov 11, 2024 | AMC | -0.83 | -1.13 | -36.1% | 14.92 | -9.5% | -10.3% | -16.6% | -18.4% | -23.1% | -23.6% | — |
| Aug 13, 2024 | AMC | -0.73 | -0.83 | -13.7% | 11.83 | -5.7% | -22.8% | -17.5% | -17.1% | -10.2% | -11.1% | — |
| May 9, 2024 | AMC | -0.68 | -0.70 | -2.9% | 14.27 | -1.5% | -5.3% | -9.4% | -8.5% | -8.4% | -7.8% | — |
| Mar 21, 2024 | AMC | -0.85 | -0.61 | +28.2% | 13.09 | -0.1% | -1.9% | -1.3% | -1.9% | -2.4% | -1.4% | — |
| Nov 7, 2023 | AMC | -0.72 | -0.57 | +20.8% | 8.75 | +0.0% | -6.7% | -15.4% | -26.3% | -27.3% | -18.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | TD Cowen | Initiates | Buy | — | $27.51 | $28.05 | +2.0% | -1.9% | -5.9% | -7.1% | -3.1% | +6.4% |
| Mar 13 | BofA Securities | Maintains | Buy → Buy | — | $26.99 | $25.81 | -4.4% | -3.0% | -4.7% | -7.3% | -11.4% | -13.7% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $37.00 | $37.35 | +0.9% | -0.5% | +1.5% | +0.9% | +1.2% | +0.4% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.11 | $47.23 | +0.3% | +0.5% | -6.0% | -13.3% | -6.0% | -7.9% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.50 | $41.81 | -6.0% | +5.9% | +6.4% | -0.5% | -8.2% | -0.5% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.14 | $40.97 | +2.1% | +2.4% | +1.8% | -2.4% | -0.8% | -1.2% |
| Sep 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $38.56 | $38.99 | +1.1% | -3.6% | -3.8% | -6.1% | -3.0% | -3.3% |
| Sep 9 | Goldman Sachs | Maintains | Buy → Buy | — | $35.93 | $36.68 | +2.1% | +7.2% | +7.3% | +3.4% | +3.3% | +0.8% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $34.84 | +0.1% | +3.2% | +10.6% | +10.8% | +6.8% | +6.6% |
| Sep 3 | Jefferies | Maintains | Hold → Hold | — | $28.86 | $28.00 | -3.0% | +1.4% | +14.8% | +20.6% | +24.5% | +33.4% |
Recent Filings
8-K · 2.02
!! High
Mineralys Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Mineralys Therapeutics reported Q1 2026 financial results and provided a corporate update, though specific revenue, earnings, or operational metrics were not disclosed in this filing summary.
May 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Multiple executive departures at IMUX and MLYS effective March 27, 2026, signal potential leadership instability that could disrupt strategic execution and warrant caution on both stocks.
Mar 31
8-K
Unknown — 8-K Filing
Mineralys achieved a major regulatory milestone with FDA acceptance of its lead hypertension drug's application, potentially enabling market entry by late 2026 and substantially increasing shareholder value if approved.
Mar 12
8-K · 8.01
!! High
Mineralys Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Mineralys Therapeutics' lorundrostat hypertension drug NDA received FDA acceptance with a December 2026 decision deadline, advancing the candidate toward potential market approval.
Mar 9
Data updated apr 26, 2026 12:39pm
· Source: massive.com